anti-HER2/HER2 bispecific ADC KM501

{
  "id": "MLC-T-ONC-010767",
  "term": "anti-HER2/HER2 bispecific ADC KM501",
  "field": "Oncology and biomedicine",
  "definition": "A therapeutic cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. Upon administration, RAS peptide cancer vaccine TG01 may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. Mutations in RAS genes are found in the majority of pancreatic cancers.",
  "synonyms": [
    "anti-HER2/HER2 antibody-drug conjugate KM501",
    "ADC KM501",
    "bispecific ADC KM501"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-her2-her2-bispecific-adc-km501/"
}